DexCom Inc.
DXCM | NASDAQ
$89.17
-$0.18 (-0.20%)
At close: Sep 21, 2026, 4:00 PM ET
$89.40
+$0.23 (+0.26%)
Pre-market:
Sep 22, 2026, 8:24 AM ET
Company Profile
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
Key Executives
| Name | Position |
|---|---|
| Jacob Steven Leach | President, CEO & Director |
| Jereme Sylvain | Executive Vice President, Chief Financial Officer & Chief Accounting Officer |
| Peter Simpson | Executive Vice President & Chief Technology Officer |
| Donald Abbey | Executive Vice President of Global Business Services, Regulatory, Medical & Clinical Affairs |
| Jon Coleman | Executive Vice President & Chief Commercial Officer |
| Keri Leone | Senior Director of Global Medical Science & Education |
| Kevin Ronald Sayer | Executive Chairman of the Board |
| Matthew Dolan | Executive Vice President of Strategy & Corporate Development |
| Michael Brown | Executive VP, Chief Legal & Compliance Officer |
| Sadie Stern | Executive VP, Chief People & Culture Officer |
| Sean Christensen | Vice President of Finance and Investor Relations |
DexCom Inc.
| Country | United States |
| IPO Date | Apr 13, 2005 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 11,050 |
| CEO | Jacob Steven Leach |
Contact Details
6340 Sequence Drive San Diego,
California 92121 United States
Stock Details
| Ticker Symbol | DXCM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001093557 |
| CUSIP Number | 252131107 |
| ISIN Number | US2521311074 |
| SIC Code | 3841 |
Recent News
- 8 days ago / businesswire.comDexcom Promotes Jereme Sylvain to Chief Operating Officer
- 8 days ago / zacks.comHere's Why You Should Retain DexCom Stock in Your Portfolio for Now
- 12 days ago / businesswire.comDexcom Appoints Glenn Boehnlein to Board of Directors
- 13 days ago / seekingalpha.comDexCom, Inc. (DXCM) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
- 15 days ago / prnewswire.comDid DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
- 20 days ago / zacks.comWhy DexCom (DXCM) is a Top Growth Stock for the Long-Term
- 21 days ago / businesswire.comDexcom Announces Upcoming Conference Presentation
- 28 days ago / zacks.comAbbott vs. DexCom: Which CGM Stock Is the Better Buy Now?
- 29 days ago / defenseworld.netGreat Lakes Advisors LLC Invests $369,000 in DexCom, Inc. $DXCM
- 1 month ago / zacks.comHere's Why DexCom (DXCM) is a Strong Momentum Stock
Add to Watchlist
Select watchlists to add or remove DXCM